The Filing Desk

Marker Therapeutics vs Cartesian Therapeutics

Marker Therapeutics MRKR · Cartesian Therapeutics RNAC · Pharmaceuticals

Marker Therapeutics reported revenue of $4 million in fiscal 2025, 1.2 times Cartesian Therapeutics' $3 million in fiscal 2025. Marker Therapeutics' revenue fell 46.2% in its latest year, and Cartesian Therapeutics' fell 92.8%. Marker Therapeutics had an operating margin of -363.4%, against -5127.1% at Cartesian Therapeutics.

Side by side

Marker TherapeuticsCartesian Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$3M
Revenue growth−46.2%−92.8%
Revenue growth a year, last 5 years47.6%−29.9%
Gross margin——
Operating margin−363.4%−5,127.1%
Net margin−343.0%−4,658.6%
Free cash flow—−$79M
Free cash flow margin—−2,838.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count70.5%49.6%
Last close$1.32$5.89
P/E at the last close——
Insider trades, last 12 months—bought $205,800, sold $258,683
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Marker TherapeuticsCartesian Therapeutics
Operating margin
Percent of revenue
Marker TherapeuticsCartesian Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Marker TherapeuticsCartesian Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Marker Therapeutics and Cartesian Therapeutics pages.